Genix Pharmaceuticals Corp. Announces AGM Results and Appoints Mahmoud Aziz to the Board and as President

Vancouver, British Columbia, May 20, 2021 — Genix Pharmaceuticals Corporation (TSX-V: GENX) (“GENIX” or the “Company”) is pleased to announce that shareholders have voted in favor of all items of business brought before them at the Company’s Annual General Meeting of Shareholders (the “AGM”) held in Vancouver, British Columbia on Wednesday May 21, 2021 (see for results).

Shareholders approved the number of directors at six, the appointment of Harbourside CPA as the Company’s independent auditor, and the annual confirmation of the Company’s 10% rolling Stock Option Plan.

The shareholders re-elected Sina Pirooz, Darryl Yea, Paul Chow, Jamie Lewin, and Kevin Bottomley to the Company’s Board of Directors. In addition, Mahmoud Aziz has been elected to the Company’s Board of Directors and appointed as its President. 

Mr. Aziz is a biochemist and possesses over 40 years of experience, at the highest levels, in the global, Indian and Chinese pharmaceuticals industry and has personally established eight successful pharmaceuticals and biopharmaceuticals factories globally, including two in Canada. Mr. Aziz is Founder, Chairman & President of The Fazio Group of Companies, a well-established and diversified, multinational organization, comprising 39 companies, actively engaged in biotechnology & pharmaceuticals research, development, commercialization and manufacturing amongst other industries.
With operations and offices in 19 countries, covering four continents, The Fazio Group employs over 10,000 people worldwide. Mr. Aziz is also founder, Chairman and President of Canagen Pharmaceuticals Inc. and Oceanix Biotechnology Corporation which are engaged in the research, development and manufacturing of generic pharmaceuticals and biopharmaceuticals in Canada, China, India and Russia. He is also founder Co-founder and Chairman of the Asia-Pacific CEO Association of Canada (APCEOC), the Canadian chapter of the global Asia Pacific CEOs Association (APCEO), headquartered in Beijing.
 The Company’s CEO, Sina Pirooz, states, “The election of Mr. Aziz to the Board and his appointment as President of Genix is an important step in the growth of the Company. His experience and knowledge in the drug and nutraceutical business and global relationships will create opportunities to develop Genix into a successful and profitable organization”.



Genix Pharmaceuticals Corporation is a highly innovative, Canadian life-sciences company focused on the acquisition, research, development, manufacturing, sales and distribution of innovative, novel and generic prescription and OTC pharmaceuticals for the ophthalmological and other attractive markets and to satisfy unmet needs. Our mission is to provide Canadian’s access to affordable, highest quality, evidence-based, novel and generic prescription drugs and OTC medicines and nutraceutical products to improve their health and quality of life. All Genix products are developed and supported by evidence-based science and clinical studies and manufactured under the strictest Good Manufacturing Practices (GMP) protocols. 

We intend to sell these products through traditional retail outlets as well as direct to consumer and e-commerce platforms.


Sina Pirooz,
CEO, Director Genix Pharmaceuticals Corporation

For more information regarding GENIX, please contact:
Kevin Bottomley, Director
Tel: +1.604.609.6199

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as, “forward‐looking statements”. Forward‐looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The Company cautions readers that forward‐looking statements, including without limitation those relating to the Company’s future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward‐looking statements.
Previous Post
Genix Pharmaceuticals Corporation Enters into Exclusive License and Supply Agreement for Canada’s First Generic Thyroid Medication
Next Post
Genix Pharmaceuticals Corporation Provides a Corporate Update To Shareholders